Sökning: "preclinical cancer models"
Visar resultat 1 - 5 av 52 avhandlingar innehållade orden preclinical cancer models.
1. Quiescent cancer cells : Three-dimensional cell models for evaluation of new therapeutics
Sammanfattning : Inadequate metabolic conditions in solid tumors lead to the formation of quiescent cancer cells that are suspended in a transient cell cycle arrest. When conditions change, quiescent cancer cells can re-enter the cell cycle and cause recurrence. LÄS MER
2. Cancer Immunotherapy : A Preclinical Study of Urinary Bladder Cancer
Sammanfattning : Bacillus Calmette Guérin (BCG), or attenuated Mycobacterium bovis, is the gold standard of immunotherapy in the clinic to treat superficial bladder cancer. However, setbacks remain due to a high recurrence rate, side effects, and BCG-refractory disease. LÄS MER
3. Anticancer Activity of Melflufen : Preclinical Studies of a Novel Peptidase-Potentiated Alkylator
Sammanfattning : Melflufen (melphalan flufenamide, chemical name L-melphalanyl-p-L-fluorophenylalanine ethyl ester hydrochloride, previously called J1) is a derivative of the classical alkylating agent melphalan. Melflufen is potentiated by hydrolytic cleavage by aminopeptidase N (APN), leading to high intracellular concentrations of alkylating moieties and subsequent cell death. LÄS MER
4. Preclinical tumor-immune modeling : For the identification of immunomodulatory drugs
Sammanfattning : For a long time, the field of cancer research was dominated by a tumor cell-centric view. That, however, changed once it became recognized that medical cancer treatment is largely influenced by the combined effect exerted on both cancer and immune cells. LÄS MER
5. Hypoxia and Stem Cells in Normal and Tumor Development
Sammanfattning : Neuroblastoma is a childhood malignancy of the sympathetic nervous system and accounts for 15% of all cancer-related deaths in children. To understand the biology behind neuroblastoma, clarify timing of cellular events and expression profiles of proteins preceding neuroblastoma initiation, we need more relevant preclinical models. LÄS MER
